During the past decade, Stamford Therapeutics Consortium conducted 25 clinical trials. In the 10-year time frame, 25 clinical trials started and 37 clinical trials were completed, i.e. on average, 148% percent of trials that started reached the finish line to date. In the past 5 years, 11 clinical trials started and 24 clinical trials were completed. i.e. 218.2% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Stamford Therapeutics Consortium" #1 sponsor was "Pfizer" with 26 trials, followed by "Bristol-Myers Squibb" with 4 trials sponsored, "BioDelivery Sciences International" with 3 trials sponsored, "Eli Lilly and Company" with 2 trials sponsored and "Ferring Pharmaceuticals" with 2 trials sponsored. Other sponsors include 14 different institutions and companies that sponsored additional 23 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Stamford Therapeutics Consortium" #1 collaborator was "Eli Lilly and Company" with 2 trials as a collaborator, "Pfizer" with 2 trials as a collaborator, "Astellas Pharma US, Inc." with 1 trials as a collaborator, "Chemo France" with 1 trials as a collaborator and "Health Decisions" with 1 trials as a collaborator. Other collaborators include 1 different institutions and companies that were collaborators in the rest 11 trials.

According to Clinical.Site data, the most researched conditions in "Stamford Therapeutics Consortium" are "Osteoarthritis" (11 trials), "Low Back Pain" (6 trials), "Arthritis" (5 trials), "Osteoarthritis, Hip" (4 trials) and "Atrial Fibrillation" (3 trials). Many other conditions were trialed in "Stamford Therapeutics Consortium" in a lesser frequency.

Most popular intervention types in "Stamford Therapeutics Consortium" are "Drug" (39 trials), "Biological" (20 trials), "Other" (8 trials), "Device" (2 trials) and "Procedure" (2 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (24 trials), "VLA15" (4 trials), "Naproxen" (3 trials), "placebo" (3 trials) and "tanezumab" (3 trials). Other intervention names were less common.

The vast majority of trials in "Stamford Therapeutics Consortium" are 54 trials for "All" genders and 2 trials for "Female" genders.

Currently, there are NaN active trials in "Stamford Therapeutics Consortium". undefined are not yet recruiting, 2 are recruiting, 7 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 36 completed trials in Stamford Therapeutics Consortium, undefined suspended trials, and 9 terminated clinical trials to date.

Out of the total trials that were conducted in Stamford Therapeutics Consortium, 0 "Phase 1" clinical trials were conducted, 15 "Phase 2" clinical trials and 39 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 3 trials, and there were also 0 trials that are defined as “Not Applicable".